1. Battaglia A, Bruni G, Ardia A, Sacchetti G (1989) Nicergoline in mild to moderate dementia. A multi-center, double-blind, placebo-controlled study. J Am Geriat Society 37: 295–302
2. Benzi G, Moretti A (1998) Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer’s disease?Eur J Pharmacol 346: 1–13
3. Coper H, Herrmann WM, Woite A (1987) Psychostimulantien, Analeptika, Nootropika. Dtsch Ärzteblatt 84: 337–342
4. Corey-Bloom J, Anand R, Veach J for the ENA 713 B352 Study Group (1998) A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriat Psychopharmacol 1: 55–65
5. Croisile B, Trillet M, Fondarai J, Laurent B, Mauguière F, Billardon M (1993) Long-term and high-dose Piracetam treatment of Alzheimer’s disease. Neurology 43: 301–305